Corvus Pharmaceuticals Statistics
Total Valuation
CRVS has a market cap or net worth of $217.69 million. The enterprise value is $179.46 million.
Important Dates
The last earnings date was Tuesday, March 25, 2025, after market close.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRVS has 68.14 million shares outstanding. The number of shares has increased by 26.99% in one year.
| Current Share Class | 68.14M |
| Shares Outstanding | 68.14M |
| Shares Change (YoY) | +26.99% |
| Shares Change (QoQ) | +2.47% |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 36.24% |
| Float | 52.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.05 |
| P/TBV Ratio | 7.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.54 |
| Quick Ratio | 1.47 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -174.85% and return on invested capital (ROIC) is -46.69%.
| Return on Equity (ROE) | -174.85% |
| Return on Assets (ROA) | -30.08% |
| Return on Invested Capital (ROIC) | -46.69% |
| Return on Capital Employed (ROCE) | -82.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.22M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +88.83% in the last 52 weeks. The beta is 0.91, so CRVS's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +88.83% |
| 50-Day Moving Average | 4.60 |
| 200-Day Moving Average | 5.06 |
| Relative Strength Index (RSI) | 30.58 |
| Average Volume (20 Days) | 690,509 |
Short Selling Information
The latest short interest is 5.39 million, so 7.91% of the outstanding shares have been sold short.
| Short Interest | 5.39M |
| Short Previous Month | 5.35M |
| Short % of Shares Out | 7.91% |
| Short % of Float | 10.31% |
| Short Ratio (days to cover) | 8.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.55M |
| Pretax Income | n/a |
| Net Income | -62.29M |
| EBITDA | -27.46M |
| EBIT | -27.55M |
| Earnings Per Share (EPS) | -$1.02 |
Full Income StatementBalance Sheet
The company has $51.96 million in cash and $1.12 million in debt, giving a net cash position of $50.84 million or $0.75 per share.
| Cash & Cash Equivalents | 51.96M |
| Total Debt | 1.12M |
| Net Cash | 50.84M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 32.57M |
| Book Value Per Share | 0.48 |
| Working Capital | 19.01M |
Full Balance SheetCash Flow
| Operating Cash Flow | -25.42M |
| Capital Expenditures | n/a |
| Free Cash Flow | -25.42M |
| FCF Per Share | -$0.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |